The role of single-pill combination therapy in light of the latest ESC/ESH 2018 guidelines for the management of arterial hypertension, with particular emphasis on preparations containing valsartan

Marcin Barylski

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

1/2019
vol. 5

Send email

Copy url:

abstract:

Review paper

The role of single-pill combination therapy in light of the latest ESC/ESH 2018 guidelines for the management of arterial hypertension, with particular emphasis on preparations containing valsartan

Marcin Barylski

Online publish date: 2019/03/20

View full text Get citation

Single-pill combination therapy is the future of antihypertensive treatment. Doctors have more and more practical experience in their use and are witnessing the implementation of new, complex preparations appearing on the pharmaceutical market, which improve cooperation with the patient, facilitate treatment, and gradually increase the proportion of people with properly controlled blood pressure. The present paper discusses the role of a single-pill combination of two (valsartan and amlodipine) or three (valsartan, amlodipine, and hydrochlorothiazide) antihypertensive drugs, in light of the latest ESC/ESH 2018 guidelines.

keywords:

The role of single-pill combination therapy in light of the latest ESC/ESH 2018 guidelines for the management of arterial hypertension, with particular emphasis on preparations containing valsartan

Marcin Barylski

single-pill combination, guidelines, valsartan, amlodipine, hydrochlorothiazide